Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

在新一届董事会换届选举完成前，公司第三届董事会成员、董事会各专门委员 会委员及高级管理人员将依照法律法规和《公司章程》等相关规定继续履行相应的 职责和义务。 公司董事会延期换届不会影响公司的正常经营，亦不会导致独立董事连任时间 超过 6 年的情形。公司将积极推进相关工作进程，并及时履行信息披露义务。 特此公告。 国科恒泰（北京）医疗科技股份有限公司 董事会 证券代码：301370 证券简称：国科恒泰 公告编号：2025-081 国科恒泰（北京）医疗科技股份有限公司 关于董事会延期换届的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）第三届董事会 任期将于 2025 年 12 月 11 日届满。鉴于公司新一届董事会换届工作尚在积极筹备 中，为保证公司董事会相关工作的连续性及稳定性，公司董事会换届选举工作将适 当延期，公司董事会各专门委员会、高级管理人员的任期相应顺延。 2025 年 12 月 10 日 ...

Core Viewpoint - Guoke Hengtai (301370) has received a utility model patent for an "Intelligent Cabinet," which will enhance the automation management of medical devices and improve management efficiency, although it will not significantly impact the company's recent operations [1] Group 1 - The patent was issued by the National Intellectual Property Administration with the patent number ZL202423182767.9 and has a validity period of ten years from the application date [1] - The announcement date of the patent grant is November 28, 2025 [1]

专利权人：国科恒泰（北京）医疗科技股份有限公司 证券代码：301370 证券简称：国科恒泰 公告编号：2025-080 国科恒泰（北京）医疗科技股份有限公司 关于取得实用新型专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的《实用新型专利证书》，具体情况如下： 实用新型名称：一种智能柜 专利号：ZL 2024 2 3182767.9 专利证书号：第 23595294 号 专利类型：实用新型专利 专利申请日：2024 年 12 月 23 日 授权公告日：2025 年 11 月 28 日 授权公告号：CN 223611963 U 专利权期限：自申请之日起十年 专利简介： 本公开的实施例提供一种智能柜。该智能柜包括柜体、柜门、触控屏、采集模 块和处理器，柜体包括通过第一放置区和第二放置区，第一放置区可以放置产品， 柜门包括相对的第一侧边和第二侧边，第一侧边固定于第一放置区的开口处，第二 侧边可沿第一侧边转动，触控屏和采集模块固定于第二放置区的外表面，处理器密 封于第 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-079 国科恒泰（北京）医疗科技股份有限公司 关于为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）对资产负债率超 过 70%的单位预计担保金额超过公司最近一期经审计净资产的 50%，前述担保均 为对公司合并报表范围内子公司的担保，财务风险处于公司可控范围内，提请投资 者充分关注担保风险。 一、担保情况概述 根据公司经营发展需要，公司于 2025 年第二次临时股东大会审议通过《关于 对外担保额度预计的议案》，同意公司向合并报表范围内子公司提供担保额度总额 为 18.55 亿元。其中，为资产负债率 70%以上的合并报表范围内子公司提供担保的 额度为 14.15 亿元；为资产负债率低于 70%的合并报表范围内子公司提供担保的额 度为 4.40 亿元。 上述额度按实际生效的金额（签订担保合同且额度有效期间内存续的担保）进 行总额控制，在担保额度总额范围内，公司子公司间可进行担保额度调剂，但调剂 发生时资 ...

Core Points - The company, Guoke Hengtai, announced a delay in the completion date of its fundraising investment project, specifically the "Information System Upgrade Project," from December 2025 to December 2027 [2] Group 1 - The third meeting of the third board of directors and the twenty-sixth meeting of the third supervisory board were held on November 27, 2025 [2] - The decision to extend the project timeline was approved within the board's authority and does not require shareholder meeting approval [2]

Group 1 - The company Guoke Hengtai (SZ 301370) announced on November 28 that its third board meeting was held on November 27, 2025, to review the proposal for amending the "Rules of Procedure for Board Meetings" [1] - For the first half of 2025, Guoke Hengtai's revenue composition was as follows: vascular interventional treatment materials accounted for 71.09%, other products 14.58%, non-vascular interventional treatment materials 5.27%, orthopedic implant materials 5.12%, and oral products 2.25% [1] - As of the report date, Guoke Hengtai's market capitalization was 5.4 billion yuan [1]

Core Viewpoint - The company announced a delay in the "Information System Upgrade Project," which was initially scheduled to be completed by December 2025, now extended to December 2027 due to external macroeconomic changes and rapid advancements in artificial intelligence technology [1] Group 1: Project Details - The planned investment amount for the project is 156.226 million yuan, funded by proceeds from the initial public offering [1] - As of October 31, 2025, the company has utilized 86.6362 million yuan of the raised funds [1] Group 2: Reasons for Delay - The delay is attributed to changes in the external macro environment, adjustments in the overall industry development pace, and the impact of rapid iterations in artificial intelligence technology on system architecture and functional requirements [1] - The company aims to prudently assess and adapt to new technological trends, leading to a cautious slowdown in the construction progress [1] Group 3: Impact of Delay - The delay does not involve changes to the total investment amount, implementing entity, project content, or purpose [1] - It is stated that the delay will not have a significant adverse impact on the company's financial status, main business, or overall fundraising arrangements, nor will it harm shareholder interests [1]

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 部分募集资金投资项目延期的核查意见 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为国科 恒泰（北京）医疗科技股份有限公司（以下简称"国科恒泰"或"公司"）首次 公开发行股票并在创业板上市的保荐机构和持续督导机构，根据《证券发行上市 保荐业务管理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相 关规定履行持续督导职责，对国科恒泰部分募集资金投资项目延期事项进行了核 查，核查情况及核查意见如下： （二）募集资金的存放情况 截至 2025 年 10 月 31 日，公司募集资金具体存放情况如下： | 开户银行 | 银行账号 | 账户类别 | 存储余额 | | --- | --- | --- | --- | | 华夏银行北京长安支行 | 10253000001112793 | 募集资金专户 | 1,466.06 | | 交通银行北京自贸试验区支行 | 1100607770130 ...

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 部分募集资金投资项目结项并将节余募集资金继续存放募集资 金专户管理的核查意见 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为国科 恒泰（北京）医疗科技股份有限公司（以下简称"国科恒泰"或"公司"）首次 公开发行股票并在创业板上市的保荐机构和持续督导机构，根据《证券发行上市 保荐业务管理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相 关规定履行持续督导职责，对国科恒泰部分募集资金投资项目结项并将节余募集 资金继续存放募集资金专户管理事项进行了核查，核查情况及核查意见如下： 一、募集资金的基本情况 根据中国证券监督管理委员会《关于同意国科恒泰（北京）医疗科技股份有 限公司首次公开发行股票注册的批复》（证监许可〔2023〕997 号），公司获准向 社会公开发行人民币普通股（A 股）股票 7,060 万股，每股面值人民币 1.00 元， 每股发行价格为人民币 13.39 元 ...